AR039005A1 - Antigenos virales - Google Patents

Antigenos virales

Info

Publication number: AR039005A1
Authority: AR; Argentina
Prior art keywords: hpv; vaccine composition; composition according; protein; proteins
Prior art date: 2002-03-18

Application number

ARP030100944A

Other languages

English (en)

Spanish (es)

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-18

Filing date

2003-03-18

Publication date

2005-02-02

2003-03-18 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2005-02-02 Publication of AR039005A1 publication Critical patent/AR039005A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Reproductive Health (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ARP030100944A 2002-03-18 2003-03-18 Antigenos virales AR039005A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0206360.0A GB0206360D0 (en)	2002-03-18	2002-03-18	Viral antigens

Publications (1)

Publication Number	Publication Date
AR039005A1 true AR039005A1 (es)	2005-02-02

Family

ID=9933201

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP030100944A AR039005A1 (es)	2002-03-18	2003-03-18	Antigenos virales

Country Status (25)

Country	Link
US (3)	US7217419B2 (ru)
EP (2)	EP1492562A2 (ru)
JP (2)	JP2005524674A (ru)
KR (2)	KR20110009249A (ru)
CN (1)	CN100528226C (ru)
AP (1)	AP1872A (ru)
AR (1)	AR039005A1 (ru)
AU (1)	AU2003218787B2 (ru)
BR (1)	BR0308444A (ru)
CA (1)	CA2479304C (ru)
EA (1)	EA011477B1 (ru)
EC (1)	ECSP045300A (ru)
GB (1)	GB0206360D0 (ru)
IL (2)	IL163814A0 (ru)
IS (1)	IS7426A (ru)
MX (1)	MXPA04009060A (ru)
MY (1)	MY139031A (ru)
NO (1)	NO20044326L (ru)
NZ (1)	NZ535085A (ru)
OA (1)	OA12787A (ru)
PL (1)	PL212981B1 (ru)
TW (1)	TW200400046A (ru)
UA (1)	UA85536C2 (ru)
WO (1)	WO2003077942A2 (ru)
ZA (1)	ZA200407029B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8956621B2 (en) *	1994-11-08	2015-02-17	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en)	1994-11-08	2014-07-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of non-hodgkins lymphoma
SI1126876T1 (sl) *	1998-10-16	2007-08-31	Glaxosmithkline Biolog Sa	Adjuvantni sistemi in vakcine
US8771702B2 (en)	2001-03-26	2014-07-08	The Trustees Of The University Of Pennsylvania	Non-hemolytic LLO fusion proteins and methods of utilizing same
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
US7858098B2 (en) *	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
CN100506999C (zh) *	2003-03-24	2009-07-01	麦克公司	Hpv31l1在酵母中的优化表达
MY140664A (en) *	2003-09-29	2010-01-15	Merck Sharp & Dohme	Optimized expression of hpv 45 l1 in yeast
US20080160040A1 (en) *	2004-04-15	2008-07-03	Ghim Shin-Je	Plant-produced compositions for treating papillomavirus infection and related methods
RU2420313C2 (ru) *	2004-06-16	2011-06-10	ГлаксоСмитКлайн Байолоджикалз с.а.	Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
US7758866B2 (en) *	2004-06-16	2010-07-20	Glaxosmithkline Biologicals, S.A.	Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
GB0413510D0 (en) *	2004-06-16	2004-07-21	Glaxosmithkline Biolog Sa	Vaccine
US8399610B2 (en) *	2004-08-05	2013-03-19	University College Cardiff Consultants Limited	HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) *	2004-08-05	2004-09-08	Uc3	A novel HPV vaccine comprising peptides from host cell proteins
EP1853307B1 (en)	2005-02-01	2016-12-14	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services,	Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
EP1877087B1 (en)	2005-04-15	2013-02-20	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
MX2007013475A (es) *	2005-04-26	2008-04-02	Glaxosmithkline Biolog Sa	Vacuna.
MX2007013472A (es) *	2005-04-26	2008-04-02	Glaxosmithkline Biolog Sa	Vacuna.
CN1328287C (zh) *	2005-12-29	2007-07-25	西安交通大学	Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
EP2059262B1 (en) *	2006-08-28	2013-08-21	Sungkyunkwan University Foundation for Corporate Collaboration	A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
EP2641613A1 (en)	2006-09-29	2013-09-25	Ligocyte Pharmaceuticals, Inc.	Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
WO2008140474A1 (en) *	2006-10-26	2008-11-20	Johns Hopkins University	Recombinant adenovirus vaccines
WO2008115631A2 (en) *	2007-02-08	2008-09-25	University Of Louisville Research Foundation, Inc.	Plant-produced compositions for treating papillomavirus infection and related methods
CA2679720A1 (en) *	2007-03-09	2008-09-18	Merck & Co., Inc.	Papillomavirus vaccine compositions
CN101293918B (zh)	2007-04-29	2013-03-27	北京万泰生物药业股份有限公司	截短的人乳头瘤病毒16型l1蛋白
CN101570571B (zh)	2007-04-29	2012-07-11	北京万泰生物药业股份有限公司	截短的人乳头瘤病毒18型l1蛋白
BRPI0810951B8 (pt) *	2007-05-29	2021-05-25	Beijing Wantai Biological Pharmacy Entpr Co Ltd	proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
EP2172488A4 (en) *	2007-06-18	2011-04-13	Shanghai Zerun Ankegens Biopharmaceutical Co Ltd	MATERIAL WITH IMMUNOGENICITY
US8088392B2 (en) *	2007-06-18	2012-01-03	Yunxu Cao	Capsid proteins and uses therefore
US10130696B2 (en)	2007-09-18	2018-11-20	Takeda Vaccines, Inc.	Method of conferring a protective immune response to norovirus
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
US8100843B2 (en) *	2009-03-24	2012-01-24	GM Global Technology Operations LLC	Shape memory polymer medical cast
JP2012530505A (ja) *	2009-06-25	2012-12-06	グラクソスミスクラインバイオロジカルズソシエテアノニム	新規ヒトパピローマウイルス（ｈｐｖ）タンパク質構築物及びｈｐｖ疾患の予防におけるそれらの使用
CN102178944A (zh) *	2010-09-17	2011-09-14	大连雅立峰生物制药有限公司	人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
MX379496B (es)	2011-07-11	2025-03-11	Takeda Vaccines Inc	Formulaciones parenterales de vacunas contra los norovirus.
CN102552897B (zh) *	2012-01-18	2013-10-30	广东华南联合疫苗开发院有限公司	一种宫颈癌预防性vlp疫苗
KR101559622B1 (ko)	2012-07-30	2015-10-13	중앙대학교 산학협력단	인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN104211782B (zh) *	2013-06-04	2017-11-17	厦门大学	截短的人乳头瘤病毒45型l1蛋白
CN107001430A (zh) *	2014-10-24	2017-08-01	哈普威克斯有限责任公司	癌症和皮肤病变治疗
US10799574B2 (en) *	2014-10-24	2020-10-13	Hpvvax. Llc	Method and composition for treating cancer or skin lesion using a vaccine
BR112018067550A2 (pt) *	2016-02-27	2019-10-01	Hpvvax, Llc.	métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9113809D0 (en)	1991-06-26	1991-08-14	Cancer Res Campaign Tech	Papillomavirus l2 protein
DK1359156T3 (da)	1991-07-19	2007-04-10	Univ Queensland	Vaccine mod humanpapillomavirus
WO1994000152A1 (en)	1992-06-25	1994-01-06	Georgetown University	Papillomavirus vaccines
US5437951A (en)	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en)	1992-09-03	1997-04-08	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric papillomavirus-like particles
EP0688227B1 (en)	1993-03-09	2005-05-25	The University Of Rochester	Production of human papillomavirus capsid protein and virus-like particles
CZ289476B6 (cs)	1993-03-23	2002-01-16	Smithkline Beecham Biologicals (S.A.)	Očkovací přípravek a způsob jeho výroby
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
PT757717E (pt) *	1994-05-16	2006-09-29	Merck & Co Inc	Vacinas de papilomavirus
AU4270196A (en) *	1994-10-07	1996-05-02	Lutz Gissmann	Papilloma virus-like particles, fusion proteins and process for producing the same
AR004464A1 (es)	1994-11-14	1998-12-16	Merck Sharp & Dohme	Un metodo para producir una proteina de capside de papilomavirus
JP3693449B2 (ja)	1996-04-05	2005-09-07	三菱製紙株式会社	抗菌防黴剤およびそれを含有する繊維状物質
AU739829B2 (en)	1997-04-08	2001-10-18	Merck Sharp & Dohme Corp.	Stabilized human papillomavirus formulations
ES2572628T3 (es) *	1997-09-05	2016-06-01	Medimmune, Inc.	Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP)
GB9720585D0 (en)	1997-09-26	1997-11-26	Smithkline Beecham Biolog	Vaccine
NZ506602A (en)	1998-03-09	2003-02-28	Smithkline Beecham Biolog S	Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
GB9806666D0 (en)	1998-03-27	1998-05-27	Stanley Margaret	Antigen preparation and use
ES2262333T3 (es) *	1998-08-14	2006-11-16	MERCK & CO., INC.	Procedimiento para purificar particulas similares a virus de papilomavirus humano.
WO2000009699A2 (en)	1998-08-14	2000-02-24	Chiron Corporation	Method for producing yeast expressed hpv types 6 and 16 capsid proteins
SI1126876T1 (sl)	1998-10-16	2007-08-31	Glaxosmithkline Biolog Sa	Adjuvantni sistemi in vakcine
DE60040727D1 (de) *	1999-02-05	2008-12-18	Merck & Co Inc	Menschliche papillomavirus impfstoff-formulierungen
US6245568B1 (en)	1999-03-26	2001-06-12	Merck & Co., Inc.	Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921147D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
OA12168A (en)	2000-01-31	2006-05-08	Smithkline Beecham Biolog	Vaccine for the prophylactic or therapeutic immunization against HIV.
US6908613B2 (en)	2000-06-21	2005-06-21	Medimmune, Inc.	Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
AU2001275438A1 (en) *	2000-07-06	2002-01-21	Georgetown University	Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0110431D0 (en) *	2001-04-27	2001-06-20	Glaxosmithkline Biolog Sa	Novel compounds
WO2003068163A2 (en) *	2002-02-14	2003-08-21	Novavax, Inc.	Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) *	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206359D0 (en) *	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
MXPA05006764A (es)	2002-12-20	2005-09-08	Glaxosmithkline Biolog Sa	Vacuna vlp l1 del vph-16 y -18.
MY140664A (en)	2003-09-29	2010-01-15	Merck Sharp & Dohme	Optimized expression of hpv 45 l1 in yeast

2002
- 2002-03-18 GB GBGB0206360.0A patent/GB0206360D0/en not_active Ceased
2003
- 2003-03-17 EP EP03712047A patent/EP1492562A2/en not_active Ceased
- 2003-03-17 MY MYPI20030925A patent/MY139031A/en unknown
- 2003-03-17 JP JP2003575995A patent/JP2005524674A/ja active Pending
- 2003-03-17 NZ NZ535085A patent/NZ535085A/en not_active IP Right Cessation
- 2003-03-17 US US10/508,222 patent/US7217419B2/en not_active Expired - Lifetime
- 2003-03-17 OA OA1200400239A patent/OA12787A/en unknown
- 2003-03-17 KR KR1020107028371A patent/KR20110009249A/ko not_active Ceased
- 2003-03-17 BR BR0308444-2A patent/BR0308444A/pt not_active Application Discontinuation
- 2003-03-17 AP APAP/P/2004/003136A patent/AP1872A/en active
- 2003-03-17 WO PCT/EP2003/002826 patent/WO2003077942A2/en not_active Ceased
- 2003-03-17 AU AU2003218787A patent/AU2003218787B2/en active Active
- 2003-03-17 UA UA20040907208A patent/UA85536C2/ru unknown
- 2003-03-17 EA EA200401064A patent/EA011477B1/ru active Protection Beyond IP Right Term
- 2003-03-17 MX MXPA04009060A patent/MXPA04009060A/es active IP Right Grant
- 2003-03-17 CN CNB038063476A patent/CN100528226C/zh not_active Expired - Lifetime
- 2003-03-17 CA CA2479304A patent/CA2479304C/en not_active Expired - Lifetime
- 2003-03-17 EP EP08171147A patent/EP2044953A1/en not_active Withdrawn
- 2003-03-17 PL PL372937A patent/PL212981B1/pl unknown
- 2003-03-17 IL IL16381403A patent/IL163814A0/xx unknown
- 2003-03-17 KR KR10-2004-7014693A patent/KR20050002868A/ko not_active Ceased
- 2003-03-18 AR ARP030100944A patent/AR039005A1/es unknown
- 2003-03-18 TW TW092105904A patent/TW200400046A/zh unknown
2004
- 2004-08-26 IS IS7426A patent/IS7426A/is unknown
- 2004-08-30 IL IL163814A patent/IL163814A/en active Protection Beyond IP Right Term
- 2004-09-02 ZA ZA2004/07029A patent/ZA200407029B/en unknown
- 2004-09-17 EC EC2004005300A patent/ECSP045300A/es unknown
- 2004-10-12 NO NO20044326A patent/NO20044326L/no not_active Application Discontinuation
2007
- 2007-05-10 US US11/746,841 patent/US7416846B2/en not_active Expired - Lifetime
2008
- 2008-07-18 US US12/175,874 patent/US7815915B2/en not_active Expired - Lifetime
2009
- 2009-12-10 JP JP2009280524A patent/JP2010090158A/ja active Pending

Also Published As

Publication number	Publication date
US20070224218A1 (en)	2007-09-27
US7416846B2 (en)	2008-08-26
US7217419B2 (en)	2007-05-15
TW200400046A (en)	2004-01-01
CN1642571A (zh)	2005-07-20
OA12787A (en)	2006-07-10
PL372937A1 (en)	2005-08-08
NZ535085A (en)	2006-08-31
IL163814A (en)	2009-07-20
JP2005524674A (ja)	2005-08-18
US20080279890A1 (en)	2008-11-13
ZA200407029B (en)	2005-11-30
NO20044326D0 (no)	2004-10-12
MY139031A (en)	2009-08-28
ECSP045300A (es)	2005-01-03
BR0308444A (pt)	2005-01-18
AP2004003136A0 (en)	2004-09-30
EP2044953A1 (en)	2009-04-08
EA200401064A1 (ru)	2005-04-28
IS7426A (is)	2004-09-15
KR20050002868A (ko)	2005-01-10
NO20044326L (no)	2004-10-14
US7815915B2 (en)	2010-10-19
PL212981B1 (pl)	2012-12-31
JP2010090158A (ja)	2010-04-22
GB0206360D0 (en)	2002-05-01
KR20110009249A (ko)	2011-01-27
CA2479304A1 (en)	2003-09-25
AU2003218787A1 (en)	2003-09-29
WO2003077942A2 (en)	2003-09-25
WO2003077942A3 (en)	2003-12-24
UA85536C2 (en)	2009-02-10
CN100528226C (zh)	2009-08-19
AP1872A (en)	2008-08-04
US20050175632A1 (en)	2005-08-11
IL163814A0 (en)	2005-12-18
EP1492562A2 (en)	2005-01-05
CA2479304C (en)	2013-10-08
AU2003218787B2 (en)	2006-04-06
EA011477B1 (ru)	2009-04-28
MXPA04009060A (es)	2005-01-25

Publication	Publication Date	Title
AR039005A1 (es)	2005-02-02	Antigenos virales
Rosalik et al.	2021	Human papilloma virus vaccination
Jansen et al.	2004	Human papillomavirus vaccines and prevention of cervical cancer
Frazer	2004	Prevention of cervical cancer through papillomavirus vaccination
Sykora et al.	2017	Papillomavirus infection and squamous cell carcinoma in horses
Frazer	2014	Development and implementation of papillomavirus prophylactic vaccines
AR077396A2 (es)	2011-08-24	EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
DK1292328T3 (da)	2008-06-16	Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
CO4810234A1 (es)	1999-06-30	Vacunas para el tratamiento de virus papiloma humano
ATE369428T1 (de)	2007-08-15	Behandlung von gebärmutterhalskrebs
FR15C0079I2 (fr)	2016-11-25	Expression optimisee de hpv 31 l1 dans la levure
RU2003101965A (ru)	2004-07-27	Лечение инфекции, вызываемой вирусом папилломы человека
DK1019510T3 (da)	2003-11-10	Vacciner på basis af porcint circovirus
TW200519203A (en)	2005-06-16	Optimized expression of HPV 58 L1 in yeast
Huber et al.	2015	A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types
EA200701633A1 (ru)	2007-12-28	Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
EP2589604A4 (en)	2013-12-18	SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS
Wang et al.	2015	Immunoprevention of human papillomavirus–associated malignancies
Banks et al.	1987	Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization
ATE465753T1 (de)	2010-05-15	Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
Einstein et al.	2004	Anogenital neoplasia in AIDS
Butterfield et al.	2021	The development of human papillomavirus (HPV) vaccines and current barriers to implementation
NZ516725A (en)	2003-03-28	Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
EP1427443A4 (en)	2006-03-08	VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
Tanweer et al.	2019	Lower genital tract precancer and cancer in hematopoietic cell transplant survivors and the role of HPV: a systematic review and future perspectives

Legal Events

Date	Code	Title	Description
2014-11-27	FB	Suspension of granting procedure